share_log

Is USANA Health Sciences, Inc.'s (NYSE:USNA) Stock Price Struggling As A Result Of Its Mixed Financials?

Is USANA Health Sciences, Inc.'s (NYSE:USNA) Stock Price Struggling As A Result Of Its Mixed Financials?

美國健康科學公司(紐交所:USNA)的股價是否因其複雜的財務狀況而陷入困境?
Simply Wall St ·  10/30 07:51

It is hard to get excited after looking at USANA Health Sciences' (NYSE:USNA) recent performance, when its stock has declined 16% over the past three months. It is possible that the markets have ignored the company's differing financials and decided to lean-in to the negative sentiment. Fundamentals usually dictate market outcomes so it makes sense to study the company's financials. In this article, we decided to focus on USANA Health Sciences' ROE.

看完優莎娜(NYSE:USNA)最近的表現後,很難感到興奮,因爲其股價在過去三個月下跌了16%。有可能市場忽略了公司不同的財務狀況,並決定傾向於負面情緒。基本面通常決定市場結果,因此研究公司的財務狀況是有意義的。在本文中,我們決定聚焦於優莎娜的roe。

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

股東應考慮的重要因素是淨資產收益率或roe,因爲它告訴他們投資的資本如何被有效地再投資。簡單來說,它用於評估公司與其股權資本相關的盈利能力。

How To Calculate Return On Equity?

如何計算股東權益報酬率?

ROE can be calculated by using the formula:

淨資產收益率可以使用以下公式進行計算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

淨資產收益率 = 淨利潤(從持續經營中獲得)÷ 股東權益

So, based on the above formula, the ROE for USANA Health Sciences is:

因此,根據以上公式,優莎娜的roe爲:

10% = US$54m ÷ US$533m (Based on the trailing twelve months to September 2024).

10% = 5400萬美元 ÷ 53300萬美元(基於截至2024年9月的過去十二個月)。

The 'return' is the yearly profit. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.10.

'回報'是年利潤。這意味着對於股東的每1美元投資,公司能夠產生0.10美元的利潤。

What Is The Relationship Between ROE And Earnings Growth?

ROE與盈利增長之間的關係是什麼?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

我們已經確定ROE服務於衡量一個公司未來收益的效率指標。根據公司再投資或「保留」的這些利潤的多少以及效果,我們便能夠評估一個公司的收益增長潛力。假設其他條件均相等,則ROE和利潤保留率均較高的公司通常比那些沒有同樣特徵的公司具有更高的增長速度。

USANA Health Sciences' Earnings Growth And 10% ROE

優莎娜的收益增長和10%的roe

When you first look at it, USANA Health Sciences' ROE doesn't look that attractive. However, its ROE is similar to the industry average of 11%, so we won't completely dismiss the company. But USANA Health Sciences saw a five year net income decline of 16% over the past five years. Remember, the company's ROE is a bit low to begin with. Hence, this goes some way in explaining the shrinking earnings.

當您第一次看到它時,優莎娜的roe看起來並不那麼吸引人。然而,其roe與11%的行業平均水平相似,因此我們不會完全忽視該公司。但在過去五年裏,優莎娜的淨利潤下降了16%。請記住,該公司的roe起點有點低。因此,在解釋收益下降方面有一定幫助。

However, when we compared USANA Health Sciences' growth with the industry we found that while the company's earnings have been shrinking, the industry has seen an earnings growth of 7.2% in the same period. This is quite worrisome.

然而,當我們將優莎娜的增長與行業進行比較時,發現該公司的收益正在下降,而行業在同一時期看到了7.2%的收益增長。這是相當令人擔憂的。

big
NYSE:USNA Past Earnings Growth October 30th 2024
紐交所:USNA過去的收益增長2024年10月30日

Earnings growth is an important metric to consider when valuing a stock. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). This then helps them determine if the stock is placed for a bright or bleak future. Is USANA Health Sciences fairly valued compared to other companies? These 3 valuation measures might help you decide.

盈利增長是評估股票價值時重要的指標。投資者需要了解市場是否已經將公司預期的盈利增長(或下降)價格化。這有助於他們判斷股票是面臨光明還是暗淡的未來。與其他公司相比,優莎娜的估值是否合理?這3個估值指標或許能幫助您做出決策。

Is USANA Health Sciences Using Its Retained Earnings Effectively?

優莎娜是否有效利用留存收益?

USANA Health Sciences doesn't pay any regular dividends, meaning that the company is keeping all of its profits, which makes us wonder why it is retaining its earnings if it can't use them to grow its business. It looks like there might be some other reasons to explain the lack in that respect. For example, the business could be in decline.

優莎娜不定期支付任何股息,這意味着公司保留了所有利潤,這讓我們想知道爲什麼公司保留了這些收益,如果不能用於業務增長的話。看起來可能有一些其他原因來解釋這種情況。比如,公司可能正在衰退。

Summary

總的來說,我們對偉明環保的表現非常滿意。具體而言,我們喜歡公司以高回報率再投資了其利潤的很大一部分。當然,這導致公司的收益大幅增長。但是,最新的行業分析師預測表明,該公司的收益預計將加速增長。

Overall, we have mixed feelings about USANA Health Sciences. While the company does have a high rate of reinvestment, the low ROE means that all that reinvestment is not reaping any benefit to its investors, and moreover, its having a negative impact on the earnings growth. With that said, we studied current analyst estimates and discovered that analysts expect the company's earnings growth to improve slightly. Sure enough, this could bring some relief to shareholders. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company.

總的來說,我們對優莎娜持有複雜看法。儘管公司有高比例的再投資,但低ROE意味着所有這些再投資並未給投資者帶來任何好處,而且對盈利增長產生了負面影響。話雖如此,我們研究了當前分析師的預測,發現分析師們預計公司的盈利增長會略有改善。毫無疑問,這可能會給股東帶來一些寬慰。要了解更多關於公司最新分析師預測的信息,請查看該公司的分析師預測可視化。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論